{
    "id": "35ce799a-fb7a-23e6-e063-6394a90af69d",
    "indications": "letrozole tablet aromatase inhibitor indicated : adjuvant treatment postmenopausal women hormone receptor positive early breast cancer ( 1.1 ) extended adjuvant treatment postmenopausal women early breast cancer received prior standard adjuvant tamoxifen therapy ( 1.2 ) first second-line treatment postmenopausal women hormone receptor positive unknown advanced breast cancer ( 1.3 )",
    "contraindications": "letrozole tablets taken orally without regard meals ( 2 ) : recommended dose : 2.5.mg daily ( 2.1 ) patients cirrhosis severe hepatic impairment : 2.5 mg every day ( 2.5 , 5.3 )",
    "warningsAndPrecautions": "packaged hdpe bottles unit dose blister package . 2.5 mg tablets – yellow round , biconvex , film coated tablets imprinted 'lt ' one side plain side . bottles 30 tablets child-resistant closure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-10 bottles 90 tablets child-resistant closure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-15 bottles 100 tablets child-resistant closure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-01 bottles 500 tablets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-16 bottles 1000 tablets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-17 unit dose blister package 100 ( 10x10 ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-43 store 25°c ( 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "pregnancy : letrozole cause fetal harm [ ( 8.1 ) ] . pregnancy : letrozole cause fetal harm [ ( 8.1 ) ] . known hypersensitivity active substance , excipients [ ( 6 ) ] . known hypersensitivity active substance , excipients [ ( 6 ) ] .",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "LETROZOLE",
            "code": "7LKK855W8I"
        }
    ],
    "organization": "Accord Healthcare, Inc.",
    "name": "Letrozole",
    "effectiveTime": "20250523",
    "indications_original": "Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 )",
    "contraindications_original": "Letrozole tablets are taken orally without regard to meals ( 2 ): Recommended dose: 2.5.mg once daily ( 2.1 ) Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day ( 2.5 , 5.3 )",
    "warningsAndPrecautions_original": "Packaged in HDPE bottles and unit dose blister package.\n                  2.5 mg tablets – yellow round, biconvex, film coated tablets imprinted with 'LT' on one side and plain on other side.\n                        Bottles of 30 tablets with a child-resistant closure ...................................................................................NDC 16729-034-10\n                        Bottles of 90 tablets with a child-resistant closure ...................................................................................NDC 16729-034-15\n                        Bottles of 100 tablets with a child-resistant closure..................................................................................NDC 16729-034-01\n                        Bottles of 500 tablets.................................................................................................................NDC 16729-034-16\n                        Bottles of 1000 tablets................................................................................................................NDC 16729-034-17\n                        Unit dose blister package 100 (10x10)...................................................................................................NDC 16729-034-43\n                  Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Pregnancy: Letrozole can cause fetal harm\n  \n   [see Use in Specific Populations (\n   \n    8.1)]\n  \n   . Pregnancy: Letrozole can cause fetal harm\n  \n   [see Use in Specific Populations (\n   \n    8.1)]\n  \n   .\n \n  \n                     Known hypersensitivity to the active substance, or to any of the excipients\n  \n   [see Adverse Reactions (\n   \n    6)]\n  \n   . Known hypersensitivity to the active substance, or to any of the excipients\n  \n   [see Adverse Reactions (\n   \n    6)]\n  \n   ."
}